SCHEMBL176297

SCHEMBL176297

CCOc1cn(-c2ccc(F)cc2)nc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.57
RAB9A P51151 6/20 0.57
LMNA P02545 1/20 0.57
KMT2A Q03164 4/20 0.51
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GLA P06280 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
DGAT1 O75907 1/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176089 0.88 NPC1 (0.56) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL168302 0.88 NPC1 (0.56) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL168121 0.87 NPC1 (0.73) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL167729 0.85 KMT2A (0.55) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL30366986 0.84 KMT2A (0.49) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL167952 0.82 KMT2A (0.47) NPC1RAB9ALMNAKMT2AKDM4E
SCHEMBL167624 0.81 AURKA (0.52) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL169117 0.81 KMT2A (0.51) NPC1RAB9ALMNAKMT2AALDH1A1
Hydrochloric Acid SCHEMBL28408091 0.80 AURKA (0.51) NPC1RAB9ALMNAKMT2AALDH1A1
SCHEMBL167526 0.80 AURKA (0.42) NPC1RAB9ALMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 EP disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 NPC1 3417/4885RAB9A 1235/4885LMNA 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.